Status:
UNKNOWN
A Study of the Value of Hybrid PET/MR and PET/CT in Prostate Cancer
Lead Sponsor:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions:
Prostate Cancer
PET/MR
Eligibility:
MALE
20+ years
Brief Summary
According to the latest data from the China National Cancer Center, prostate cancer has become the most common tumor in the urinary system since 2008. However, conventional imaging techniques includin...
Detailed Description
According to the latest data from the China National Cancer Center, prostate cancer has become the most common tumor in the urinary system since 2008. However, conventional imaging techniques includin...
Eligibility Criteria
Inclusion
- Patients suspected of or diagnosed with prostate cancer
Exclusion
- Acute systemic diseases and electrolyte disorders
- Patients with known malignancy in other organs
- Patients with severe claustrophobia or unstable vital sigh
- Other serious comorbidities evaluated by primary investigator
Key Trial Info
Start Date :
April 26 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03756077
Start Date
April 26 2018
End Date
December 31 2023
Last Update
February 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiaoli Lan
Wuhan, Hubei, China, 430022